452 reports of this reaction
2.0% of all FREMANEZUMAB VFRM reports
#10 most reported adverse reaction
FATIGUE is the #10 most commonly reported adverse reaction for FREMANEZUMAB VFRM, manufactured by Teva Pharmaceuticals USA, Inc.. There are 452 FDA adverse event reports linking FREMANEZUMAB VFRM to FATIGUE. This represents approximately 2.0% of all 22,887 adverse event reports for this drug.
Patients taking FREMANEZUMAB VFRM who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for FREMANEZUMAB VFRM, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for FREMANEZUMAB VFRM:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 452 FDA reports for FREMANEZUMAB VFRM. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 2.0% of all adverse event reports for FREMANEZUMAB VFRM, making it a notable side effect.
If you experience fatigue while taking FREMANEZUMAB VFRM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.